Welcome to our dedicated page for BIONTECH SEC filings (Ticker: BNTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioNTech SE (BNTX) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including current reports on Form 6-K and annual reports on Form 20-F. As a foreign private issuer listed on Nasdaq, BioNTech uses these filings to report financial results, material agreements, strategic transactions and key corporate presentations.
Through its 6-K filings, BioNTech has furnished quarterly financial statements and operating reviews, detailing revenues from its COVID-19 vaccine franchise, collaboration income and research and development spending related to its oncology and mRNA programs. Other 6-Ks incorporate press releases and presentations covering topics such as third quarter results, R&D and AI-focused events, and strategic business updates presented at investor conferences.
Regulatory filings also document major corporate transactions and collaborations. For example, BioNTech has filed 6-Ks that attach press releases on its public exchange offer for all outstanding shares of CureVac N.V. and the subsequent completion of that acquisition, as well as a detailed description of the amended and restated global co-development and co-commercialization agreement with Bristol Myers Squibb for the bispecific antibody pumitamig (BNT327/BMS986545). These documents outline development responsibilities, cost-sharing, profit and loss sharing and intellectual property licensing arrangements.
Investors can use this page to review filings related to clinical and strategic milestones, including R&D day presentations, AI strategy updates and oncology pipeline overviews that are furnished as exhibits to Form 6-K. Stock Titan enhances access to these materials by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries that explain the key points of lengthy documents such as financial reports, collaboration agreements and transaction-related disclosures.
For those researching BNTX stock, the filings page is a resource for understanding how BioNTech describes its business, reports its financial performance, and records significant agreements and acquisitions in the official SEC record.
BioNTech SE has called a virtual Annual General Meeting for May 15, 2026, where shareholders will vote electronically via an Investor Portal. The meeting will present 2025 financial statements and a proposal to carry forward the EUR 6,901,677,892.10 balance sheet profit in full.
Key resolutions include expanding the Supervisory Board from six to eight members, re-electing three current members, and electing two new oncology and clinical-development specialists. Shareholders will also vote on extending authorization to hold virtual AGMs and replacing the remaining 2025 capital authorization with a new Authorized Capital 2026 of up to EUR 129,513,743 (50% of current share capital).
The agenda further covers approval of the 2025 compensation report, appointment of EY as auditor for 2026, and a domination and profit-and-loss transfer agreement with wholly owned subsidiary BioNTech Discovery GmbH. As of the notice date, share capital comprises 259,027,487 registered shares and 252,884,261 voting shares after treasury holdings.
BioNTech SE filed Amendment No. 1 to its Form 20-F to correct a typographical error in the date of EY’s audit opinions, changing them from March 10, 2025 to March 10, 2026 and updating the most recent practicable ordinary share count to 252,884,261.
The amendment does not change any financial statements or other disclosures for the year ended December 31, 2025. EY issued unqualified opinions on the consolidated IFRS financial statements and on internal control over financial reporting as of December 31, 2025.
The audited financials include €2.0 billion of collaboration revenue from COVID-19 vaccine sales, €0.6 billion of revenue from the Bristol-Myers Squibb collaboration, and business combinations such as the Biotheus and CureVac acquisitions with significant recognized intangible assets.
BioNTech SE filed an initial insider ownership report for director Nicola Claire Blackwood on Form 3. The filing identifies her role as a director and, in the data provided, does not report any equity transactions or derivative positions, serving mainly as a baseline disclosure of her status as an insider.
BioNTech SE director Anja Morawietz has filed an initial ownership report showing a modest equity stake in the company. The filing lists beneficial ownership of 200 ordinary shares held directly and an additional 40 ordinary shares held indirectly by her immediate family, as described in the footnote. This Form 3 does not report any recent share purchases or sales; it simply establishes her current holdings as she becomes a reporting insider.
BioNTech SE director Rudolf Staudigl filed an initial ownership report showing he holds 400 Ordinary Shares of the company. These shares are reported as held directly, and the filing does not list any recent purchase, sale, or other transaction activity, only the existing position.
BioNTech SE Chief Executive Officer Ugur Sahin filed an initial ownership report detailing his direct, indirect and derivative interests in the company’s ordinary shares. The filing shows indirect ownership of 40,132,788 ordinary shares held through Medine GmbH, which he wholly owns and may be deemed to beneficially own. It also lists 858,209 ordinary shares held directly.
In addition, Sahin holds several option and phantom option awards and performance share units tied to BioNTech ordinary shares, with various exercise prices and expiration dates extending to 2035. These awards generally vest in equal annual installments over four years and are subject to performance-based and other conditions.
BioNTech SE filed an initial beneficial ownership report for Chief Financial Officer Ramon Zapata Gomez on Form 3. This filing formally registers him as an officer subject to insider reporting rules. The available data shows no transactions or derivative positions reported in this Form 3 excerpt.
BioNTech SE officer Ryan James Timothy Patrick filed an initial ownership report showing existing equity awards and share holdings. He holds options over 25,459 and 8,838 ordinary shares with exercise prices of EUR 75.91 and EUR 93.35 that vest annually over four years and become exercisable four years after grant, subject to performance and other conditions. He also holds 11,047 performance share units, plus restricted stock units over 740 and 750 ordinary shares that vest in equal annual installments over four years with a four-year waiting period. In addition, he directly owns 4,795 ordinary shares, including 3,990 held jointly with his spouse.
BioNTech SE filed an initial insider ownership report for Chief People Officer Kylie Jimenez. This Form 3 establishes her status as a reporting person under U.S. securities rules. The filing does not list any transactions or option exercises; it simply opens ongoing disclosure of future activity.
BioNTech SE is highlighting progress in its late-stage lung cancer portfolio with new clinical data to be presented at the European Lung Cancer Congress 2026 in Copenhagen. The company will showcase programs spanning immunomodulators, antibody-drug conjugates and mRNA-based cancer immunotherapies across multiple lung cancer settings.
Key updates include pumitamig, a PD-L1×VEGF-A bispecific immunomodulator with encouraging antitumor activity and survival outcomes in several Phase 1/2 trials in China, supporting ongoing global ROSETTA Lung-01 and Lung-02 trials. Gotistobart, a CTLA-4–targeting candidate, showed clinically meaningful antitumor activity and a 54% reduction in risk of death versus standard chemotherapy in stage 1 of the global Phase 3 PRESERVE-003 study in squamous NSCLC.
BioNTech also reported first clinical data for BNT326/YL202, a HER3-targeted ADC, in advanced NSCLC with antitumor activity and favorable safety, backing a combination trial with pumitamig. Overall, BioNTech is running 16 lung cancer trials, including four pivotal Phase 3 and five novel-novel combination studies.